Data from Clonal Architecture of <i>EGFR</i> Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

Abstract

<div>AbstractPurpose:<p>Clonal architecture is fundamental for the understanding of cancer biology and therapy; however, multiregional sampling in advanced-stage cancers is not always applicable. This prospective clinical trial was to investigate whether paired tissue and circulating tumor DNA (ctDNA) could describe the clonal architecture of advanced non–small cell lung cancer (NSCLC) and its association with clinical outcome (NCT03059641).</p>Patients and Methods:<p>Paired tumor and plasma ctDNA samples were sequenced by target-capture deep sequencing of 1,021 genes. Clonal dominance analysis was performed on the basis of PyClone.</p>Results:<p>Overall, 300 treatment-naïve patients with stage IIIB–IV NSCLC were recruited from 14 centers. Of the 94 patients with available ctDNA data for <i>EGFR</i> clonal architecture analysis, 72 (76.6%) showed <i>EGFR</i> as the dominant clone. The median progression-free survival was longer for these patients than for the 22 patients whose <i>EGFR</i> was nondominant clone [11 vs. 10 months; HR, 0.46; 95% confidence interval (CI), 0.24–0.88; <i>P</i> = 0.02]. The difference was more significant if both tissue and ctDNA defined <i>EGFR</i> as dominant clone (<i>n</i> = 43) versus those not (<i>n</i> = 8; 11 vs. 6 months; HR, 0.13; 95% CI, 0.04–0.50; <i>P</i> = 0.003). Moreover, multivariate Cox proportional HR analysis demonstrated <i>EGFR</i> clonal architecture as an independent prognostic indicator of the efficacy of EGFR-tyrosine kinase inhibitors (TKIs).</p>Conclusions:<p>Paired tissue and ctDNA could be analyzed for clonal architecture in advanced cancer. <i>EGFR</i> mutations do not always make up a dominant clone in advanced NSCLC, which was associated with the efficacy of EGFR-TKIs in NSCLC.</p></div>